Arthur Leibowitz Purchases 5,000 Shares of Organogenesis (NASDAQ:ORGO) Stock

Organogenesis (NASDAQ:ORGO) Director Arthur Leibowitz purchased 5,000 shares of the company’s stock in a transaction that occurred on Monday, March 9th. The shares were purchased at an average cost of $2.68 per share, for a total transaction of $13,400.00. Following the purchase, the director directly owned 291,014 shares in the company, valued at $779,917.52. This trade represents a 1.75% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Organogenesis Stock Performance

NASDAQ:ORGO opened at $2.64 on Friday. The firm has a 50-day moving average of $3.70 and a two-hundred day moving average of $4.45. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.62 and a quick ratio of 3.32. The stock has a market cap of $339.61 million, a P/E ratio of 33.00 and a beta of 1.43. Organogenesis has a 1-year low of $2.61 and a 1-year high of $7.08.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.21 by $0.10. Organogenesis had a return on equity of 21.41% and a net margin of 5.32%.The business had revenue of $225.61 million for the quarter, compared to analysts’ expectations of $172.68 million. On average, research analysts expect that Organogenesis will post -0.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Organogenesis

Several institutional investors have recently modified their holdings of the company. Quarry LP acquired a new stake in shares of Organogenesis in the 3rd quarter worth about $25,000. State of Alaska Department of Revenue bought a new stake in Organogenesis in the 3rd quarter valued at about $25,000. Flagship Harbor Advisors LLC acquired a new position in Organogenesis during the 4th quarter valued at about $34,000. Federated Hermes Inc. boosted its stake in Organogenesis by 52.8% during the 4th quarter. Federated Hermes Inc. now owns 8,541 shares of the company’s stock valued at $44,000 after purchasing an additional 2,953 shares during the period. Finally, Mercer Global Advisors Inc. ADV bought a new position in Organogenesis in the 4th quarter worth about $57,000. Institutional investors own 49.57% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Weiss Ratings upgraded Organogenesis from a “sell (d+)” rating to a “hold (c)” rating in a research note on Friday, February 27th. Wall Street Zen upgraded shares of Organogenesis from a “hold” rating to a “buy” rating in a research note on Sunday, March 8th. Finally, BTIG Research cut their price target on shares of Organogenesis from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $8.50.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.